Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2109 vs Darzalex in Healthy Chinese Male Subjects
NCT07400744Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, randomised, double-blind trial of QL2109 in multiple myeloma (MM) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity at Day 71. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QL2109
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07400744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400744.